Addex Therapeutics (ADXN) Shares Outstanding (Weighted Average) (2018 - 2025)

Addex Therapeutics has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $185.0 million for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $185.0 million, up 26.3% year-over-year; the trailing twelve-month figure through Dec 2025 was $185.0 million (up 26.3% YoY), and the FY2025 annual result was $178.3 million, up 21.75% from the prior year.
• Shares Outstanding (Weighted Average) came in at $185.0 million for Q4 2025 at Addex Therapeutics, down from $334.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $334.1 million in Q3 2025 to a low of $313973.0 in Q3 2021.
• The 5-year median for Shares Outstanding (Weighted Average) is $234.6 million (2022), against an average of $192.8 million.
• Across the five-year window, Shares Outstanding (Weighted Average) slumped 99.12% in 2021 and soared 90433.76% in 2022, its largest moves.
• Addex Therapeutics' Shares Outstanding (Weighted Average) stood at $41.1 million in 2021, then soared by 94.81% to $80.1 million in 2022, then surged by 76.28% to $141.1 million in 2023, then grew by 3.76% to $146.4 million in 2024, then advanced by 26.3% to $185.0 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $185.0 million (Q4 2025), $334.1 million (Q3 2025), and $322.4 million (Q2 2025), per Business Quant data.